尿激酶注射液治疗视网膜分支静脉阻塞疗效观察

Clinical Observation of Intravitreous Injection of Urokinase for Branch retinal Vein Occlusion

目的：观察小剂量尿激酶注射液治疗视网膜分支静脉阻塞的临床疗效。方法：对我院自2006年7月-2010年6月经临床诊断为视网膜分支静脉阻塞的住院患者46例（46眼）,均为发病后第1时间就诊,荧光血管造影无视网膜新生血管产生,凝血系统功能检查确定无尿激酶全身及局部用药禁忌的情况下给予尿激酶注射液2万单位静脉注射,每天1次,共10天。1个月再次行荧光血管造影,对用药前后视盘水肿及黄斑水肿变化进行分析,以及视力变化情况进行统计学分析。结果：24例患者视力均有不同程度的提高视盘及黄斑水肿明显减轻,统计学分析P〈0.05,有统计学意义。结论：小剂量尿激酶注射液对保护视功能,改善视网膜静脉阻塞微循环障碍有效。

Objective： To observe the clinical efficacy of intravitreous injection of urokinase（UK） treat branch retinal vein occlusion.（BRVO）.Methods： Retrospectively analysis was taken in 46 patients（46 eyes） with branch retinal vein occlusion by fundus fluorescein angiography（FFA）.The levels of papilloedema and macular edema were classified by fundus fluorescein angiography,evaluated blood system.The body have no urokinase contraindication.The therapy of intravitreous injection of urokinase 20000u once a day.After ten days,we assessed eyes sight,papilloedema and macular edema.Results： The vision of these eyes elevated with different degrees,papilloedema and macular edema improved obviously.Conclusion： Intravitreous injection of urokinase to treat branch retinal vein occlusion is an efficacious clinical therapy.